How Elon Musk’s Twitter acquisition quashed the chilling news of the FDA’s approval of remdesivir for young children.
On April 25, 2022, there were two big items in the news. One was that Elon Musk “bought” Twitter. This was really big news. It was everywhere.
The other was that the U.S. Food and Drug Administration (FDA) expanded approval of the first and only COVID-19 treatment to include very young children.
What might that treatment be?
No, it isn’t fresh air, exercise and healthy eating habits.
It’s remdesivir, packaged under the name Veklury.
The news of Veklury’s approval is so much more important than Musk’s acquisition of Twitter, but according to the media you would never know it. That’s because sensationalism sells where unconscionable truths do not.
Who makes Veklury?
A company called Gilead Sciences, is a “biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases. Gilead has operations in more than 30 countries worldwide, with headquarters in Foster City, California.”
Let’s take a look at the top investors in Gilead as of December 30, 2021:
Blackrock Inc. shares: 9.49%
Capital Research Global Investors: 8.55%
Vanguard Group, Inc.: 8.44%
State Street Corporation: 4.58%
Well, isn’t it funny how those same companies keep popping up as top investors in every type of industry?
LET’S TAKE A LOOK AT SOME FACTS ABOUT REMDESIVIR:
Study after study has shown that remdesivir causes kidney failure. The National Library of Medicine noted that:
Remdesivir is a novel adenosine-like nucleotide analogue… with an uncertain clinical relevance. In clinical trials and case series, acute kidney injury (AKI), including renal replacement, has been frequently reported.
Kidney International noted:
Compared with the use of chloroquine, hydroxychloroquine…the use of remdesivir was associated with an increased reporting of kidney disorders.
On July 16, 2021, it a large remdesivir study found that:
A lack of consensus regarding the antiviral drug remdesivir to treat people with COVID-19 leaves doctors without clear direction on one of the few treatments for the illness the FDA has granted emergency use authorization.
The latest research comes from Michael Ohl, MD, and colleagues who studied a large group of Veterans Administration patients hospitalized with COVID-19. Compared with a matched group of veterans who did not receive the antiviral, remdesivir did not significantly improve survival rates
It was back in October of 2020 that Science.org came out with this headline:
“The ‘very, very bad look’ of remdesivir, the first FDA-approved COVID-19 drug, stating ‘The Food and Drug Administration held no advisory meeting on antiviral, and the European Union signed a contract without knowing of a failed trial.’
At best, one large, well-designed study found remdesivir modestly reduced the time to recover from COVID-19 in hospitalized patients with severe illness. A few smaller studies found no impact of treatment on the disease whatsoever. Then, on 15 October… the fourth and largest controlled study delivered what some believed was a coup de grâce: The World Health Organization’s (WHO’s) Solidarity trial showed that remdesivir does not reduce mortality or the time COVID-19 patients take to recover.
That deal that the FDA signed with Europe was worth a cool $1 billion. Two weeks after the deal was inked, on October 22, 2020, the FDA approved remdesivir, the first drug to receive that status.
The decision to go with remdesivir baffled scientists since studies had shown no worth for the drug in combatting COVID.
Nine members of the FDA Panel tasked with determining acceptable COVID-19 treatments disclosed financial ties to Gilead. At least 7 other members failed to disclose their financial ties to Gilead while a number of other panel members appeared to have links to Gilead that required no disclosure.
Together, Gilead-linked individuals made up a majority of the panel that decided to approve remdesivir.
It also should be noted that the price tag for remdesivir is $5000, or $3,120 with private insurance, versus approximately $37 for say, Hydroxychloroquine, or even less for Ivermectin. It should therefore be no surprise which drug the corrupt FDA chose to approve while discrediting the others.
Remdesivir isn’t a pill. It isn’t easy to take. It has to be injected and monitored in a clinical setting.
As for side effects, the NIH website says that Remdesivir can cause gastrointestinal symptoms (e.g., nausea), elevated transaminase levels (causing inflammation of the liver), an increase in prothrombin time without a change in the international normalized ratio, and hypersensitivity reactions.
In plain English, over and over we see this warning: liver failure. Study after study sounded alarms as noted in Forbes article The Strange Story of Remdesivir, the Drug that doesn’t work.
A September 2021 Lifesite article said, “the high mortality rate and frequency of adverse effects associated with Remdesivir ‘begs the question … Why is this the protocol in American hospitals?’“
A lot happened in October of 2020 leading up to remdesivir’s approval by the FDA. For those of you who don’t remember, the best sales pitch for remdesivir came at the beginning of that month when President Donald Trump announced he had contracted COVID-19 and was admitted to Walter Reed National Military Medical Center in Bethesda, Maryland.
On October 3rd, 2020, it was announced that Trump was receiving an experimental antiviral for Covid-19 called remdesivir as “part of a double-barreled treatment plan that includes an antibody cocktail meant to give the president’s immune system a boost to fight off the coronavirus.”
We all held our breath as Trump fought off the virus and made a miraculous recovery. I, for one, will never forget that inspiring moment when he returned from hospital, stood on the balcony of the White House and defiantly tore off his mask.